Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Wave Life Sciences Ltd.

A Tale of Two Biotech Giants: SG&A Expenses Over Time

In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Gilead Sciences, Inc. and Wave Life Sciences Ltd. from 2014 to 2023. Gilead Sciences, a leader in antiviral drugs, has seen its SG&A expenses grow by over 100% during this period, reflecting its expansive operations and market reach. In contrast, Wave Life Sciences, a smaller player focusing on genetic medicines, has experienced a more modest increase of around 1,600%, indicative of its growth phase and increasing market activities.

Key Insights

• Gilead Sciences: From 2014 to 2023, SG&A expenses rose from approximately $3 billion to $6 billion, highlighting its robust market presence.
• Wave Life Sciences: Starting at just under $3 million in 2014, expenses surged to over $50 million by 2023, showcasing its rapid expansion.

This comparison underscores the diverse strategies and growth trajectories within the biotech sector.